0228338 室性心动过速时再进入线路几何学周期长度和慢传导区周期长度的动态关系/Ciaccio E J//Circulation.-2001,103(7).-1017～1024 医科图0228339 抗自主神经膜受体抗体在室性心律失常和窦房结功能不全时的不同外观及生物化学的效应...0228338 室性心动过速时再进入线路几何学周期长度和慢传导区周期长度的动态关系/Ciaccio E J//Circulation.-2001,103(7).-1017～1024 医科图0228339 抗自主神经膜受体抗体在室性心律失常和窦房结功能不全时的不同外观及生物化学的效应/Chiale P A//Circulation.-2001,103(13).-1765～1771展开更多
Sudden cardiac death （SCD） from ventricular fibrillation （VF） during coronary artery disease （CAD） is a leading cause of total and cardiovascular mortality, and in more than half of SCD cases VF occurs as the fi...Sudden cardiac death （SCD） from ventricular fibrillation （VF） during coronary artery disease （CAD） is a leading cause of total and cardiovascular mortality, and in more than half of SCD cases VF occurs as the first symptom of CAD. Several epidemiological studies have shown that sudden death of a family member is a risk factor for SCD and VF during acute myocardial infarction （MI）, independent of traditional risk factors including family history of MI, suggesting a genetic component in the susceptibility to VF. To prevent SCD and VF due to MI, we need a better understanding of the genetic and molecular mechanisms causing VF in this apparently healthy population. Even though new insights and technologies have become available, the genetic predisposition to VF during MI remains poorly understood. Findings from a variety of different genetic studies have failed to reach reproducibility, although several genetic variants, both common and rare variants, have been associated to either VF or SCD. For this review, we searched PubMed for potentially relevant articles, using the following MeSH-terms： ＂sudden cardiac death＂, ＂ventricular fibrillation＂, ＂out-of-hospital cardiac arrest＂, ＂myocardial infarction, myocardial ische- mia＂, ＂coronary artery disease＂, and ＂genetics＂. This review describes the epidemiology and evidence for genetic susceptibility to VF due to MI.展开更多
1 Introduction Heart rhythm disorders, including bradyarrhythmias, atrial fibrillation （AF）, and ventricular arrhythmias, become increasingly common with aging and represent important causes of morbidity and mortal...1 Introduction Heart rhythm disorders, including bradyarrhythmias, atrial fibrillation （AF）, and ventricular arrhythmias, become increasingly common with aging and represent important causes of morbidity and mortality among older adults.[1-3] Older adults are particularly predisposed to these conditions due to the high prevalence of cardiovascular disease in con- junction with age-related changes that occur in the heart and cardiac conduction system.展开更多
Background: Recent data suggest that beta-blockers can be beneficial in patients with chronic heart failure (CHF). Atrial fibrillation (AF) is present in a significant number of patients with CHF and is associateing w...Background: Recent data suggest that beta-blockers can be beneficial in patients with chronic heart failure (CHF). Atrial fibrillation (AF) is present in a significant number of patients with CHF and is associateing with significant morbidity and increasing mortality rates. Thus it is necessary to establish therapy to improve the poor prognosis in this high-risk population, but a specific benefit of beta-blockers to the subset with concomitant AF and CHF has been little demonstrated. Objective: To examine the effects of Bisoprolol (6 months treatment) on the ventricular function and hemodynamics in patients with AF and CHF. Methods: 84 patients with stable CHF (NYHA≤Ⅲ class) and AF were assigned to Treated Group( n = 37) or Control group Ⅰ ( n = 22, 24-hour heart mean rate < 70/min) or Control Group Ⅱ ( n = 25, 24-hour heart mean rate ≥ 70/min) . All patients were given the basic therapy for CHF, and Treated Group received Bisopolol. Clinical and echocardiographic variables were measured in 3 groups at baseline and after 6 months, and the results were compared . Results: After 6 months of treatment with Bisoprolol, left ventricular ejection fraction (LVEF) and NYHA class had significandy improved (P < 0.05), and a trend towards a reduction in combined end point of death or CHF hospitalization was also observed (P < 0.20) in Treated Group; The increase of LVEF in Treated Group were associated with a reduction in mitral regurgitation degree and left atrial volume; The heart rate in mean 24-hour and at peak exercise decreased in Treated Group, but were similar to that in Control Group Ⅰ. Conclusion: 6 months of Bisoprolol therapy resulted in an improvement in the NYHA class and LVEF, and also showed a trend towards a reduction in hospitalization or death. The beneficial effects of Bisoprolol on patients with AF and CHF may be partly mediated by improvement of ventricular diastolic function.展开更多
文摘0228338 室性心动过速时再进入线路几何学周期长度和慢传导区周期长度的动态关系/Ciaccio E J//Circulation.-2001,103(7).-1017～1024 医科图0228339 抗自主神经膜受体抗体在室性心律失常和窦房结功能不全时的不同外观及生物化学的效应/Chiale P A//Circulation.-2001,103(13).-1765～1771
文摘Sudden cardiac death （SCD） from ventricular fibrillation （VF） during coronary artery disease （CAD） is a leading cause of total and cardiovascular mortality, and in more than half of SCD cases VF occurs as the first symptom of CAD. Several epidemiological studies have shown that sudden death of a family member is a risk factor for SCD and VF during acute myocardial infarction （MI）, independent of traditional risk factors including family history of MI, suggesting a genetic component in the susceptibility to VF. To prevent SCD and VF due to MI, we need a better understanding of the genetic and molecular mechanisms causing VF in this apparently healthy population. Even though new insights and technologies have become available, the genetic predisposition to VF during MI remains poorly understood. Findings from a variety of different genetic studies have failed to reach reproducibility, although several genetic variants, both common and rare variants, have been associated to either VF or SCD. For this review, we searched PubMed for potentially relevant articles, using the following MeSH-terms： ＂sudden cardiac death＂, ＂ventricular fibrillation＂, ＂out-of-hospital cardiac arrest＂, ＂myocardial infarction, myocardial ische- mia＂, ＂coronary artery disease＂, and ＂genetics＂. This review describes the epidemiology and evidence for genetic susceptibility to VF due to MI.
文摘1 Introduction Heart rhythm disorders, including bradyarrhythmias, atrial fibrillation （AF）, and ventricular arrhythmias, become increasingly common with aging and represent important causes of morbidity and mortality among older adults.[1-3] Older adults are particularly predisposed to these conditions due to the high prevalence of cardiovascular disease in con- junction with age-related changes that occur in the heart and cardiac conduction system.
文摘Background: Recent data suggest that beta-blockers can be beneficial in patients with chronic heart failure (CHF). Atrial fibrillation (AF) is present in a significant number of patients with CHF and is associateing with significant morbidity and increasing mortality rates. Thus it is necessary to establish therapy to improve the poor prognosis in this high-risk population, but a specific benefit of beta-blockers to the subset with concomitant AF and CHF has been little demonstrated. Objective: To examine the effects of Bisoprolol (6 months treatment) on the ventricular function and hemodynamics in patients with AF and CHF. Methods: 84 patients with stable CHF (NYHA≤Ⅲ class) and AF were assigned to Treated Group( n = 37) or Control group Ⅰ ( n = 22, 24-hour heart mean rate < 70/min) or Control Group Ⅱ ( n = 25, 24-hour heart mean rate ≥ 70/min) . All patients were given the basic therapy for CHF, and Treated Group received Bisopolol. Clinical and echocardiographic variables were measured in 3 groups at baseline and after 6 months, and the results were compared . Results: After 6 months of treatment with Bisoprolol, left ventricular ejection fraction (LVEF) and NYHA class had significandy improved (P < 0.05), and a trend towards a reduction in combined end point of death or CHF hospitalization was also observed (P < 0.20) in Treated Group; The increase of LVEF in Treated Group were associated with a reduction in mitral regurgitation degree and left atrial volume; The heart rate in mean 24-hour and at peak exercise decreased in Treated Group, but were similar to that in Control Group Ⅰ. Conclusion: 6 months of Bisoprolol therapy resulted in an improvement in the NYHA class and LVEF, and also showed a trend towards a reduction in hospitalization or death. The beneficial effects of Bisoprolol on patients with AF and CHF may be partly mediated by improvement of ventricular diastolic function.
